Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) in Primary Infant Vaccination.

Trial Profile

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) in Primary Infant Vaccination.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Acronyms DTPA-HBV-IPV-124 PRI
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Nov 2012 Status of the extension trial (NCT01453998) is completed.
    • 04 Oct 2012 Status of the extension trial (NCT01453998) is active, no longer recruiting.
    • 06 Aug 2012 Actual patient number changed from 721 to 720 as reported by ClinicalTrials.gov (Parent trial: NCT01248884).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top